As the pace of Fragile X research accelerates, the prospects of finding effective treatments and a cure for Fragile X and autism continue to improve. FRAXA funded research teams are leading the way.

FRAXA funded research spans the spectrum of basic science, pre-clinical, and clinical research — all coordinated to make the most of each dollar. We maintain a diversified approach, developing several treatment strategies in parallel, since success is never certain in developing a single drug. We continue to fund research to define the precise defect in the Fragile X brain, because these basic studies may yield additional important therapeutic targets.

In the words of FRAXA Scientific Advisor, Dr. Justin Fallon, “Fragile X is poised to become a triumph for translational research and the design of rational therapeutics for brain disease.”